Squarepoint Ops Adds $16M in AnaptysBio, Inc. ($ANAB)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Squarepoint Ops increased its position in AnaptysBio, Inc. ($ANAB) by 149.83% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 401,555 shares of AnaptysBio, Inc. after buying 240,824 shares during the quarter. Squarepoint Ops's holdings in AnaptysBio, Inc. were worth $27.33 million as of its most recent filing.
AnaptysBio, Inc. Stock Up 20.9%
Shares of AnaptysBio, Inc. ($ANAB) traded around $68.05 on Saturday, up 20.9% for the day.
AnaptysBio, Inc. Earnings
Analysts Set New Price Targets
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Get AnaptysBio, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ANAB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.